Clinical trial · Observational
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
NCT04723095CI-TRIAL-00104656NeCTuRrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 15, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260915-000001
Summary
Brief summary (as posted)
This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.
Conditions
Conditions (22)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Large Cell Neuroendocrine Carcinoma | Cervical Large Cell Neuroendocrine Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Cervical Neuroendocrine Carcinoma | Cervical Neuroendocrine Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Cervical Small Cell Carcinoma | Cervical Small Cell Neuroendocrine Carcinoma | ALIAS | 0.90 |
| Cervical Undifferentiated Carcinoma | Cervical Undifferentiated Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Stage IA1 Cervical Cancer AJCC v8 | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
| Stage IA2 Cervical Cancer AJCC v8 | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
| Stage IA Cervical Cancer AJCC v8 | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
| Stage IB1 Cervical Cancer AJCC v8 | Malignant Cervical Neoplasm |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Follow-Up | Other | — | UNRESOLVED |
| Medical Chart Review | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational (medical chart review)
- description
- Patients' medical records are reviewed retrospectively and prospectively. All prospective patients will be contacted via email, telephone, or U.S. Mail on case by case basis for up to 10 years to check status of disease and any further treatment received. Project staff can also access the patient's M. D. Anderson Epic medical record for updates. Request for additional clinic and treatment notes will be submitted to external medical institutions listed in the physician information form in order to access updated notes for non- M. D. Anderson patients.
- interventionNames
- Other: Follow-Up
- Other: Medical Chart Review
Primary outcomes (3)
- measure
- Disease characterization data
- timeFrame
- through study completion, an average of 1 year
- description
- Information collected from retrospective and prospective review of medical records.
- measure
- Patient treatment data
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes: * Small cell neuroendocrine carcinoma * Large cell neuroendocrine carcinoma * Undifferentiated high-grade neuroendocrine carcinoma * Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study * Patients with all stages of disease are considered eligible * Patients who do not speak English can be eligible if accompanied by an institutional interpreter * Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible * Patient may be residents of any country and be of any ethnic background * Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website * Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate * Next of kin or legal authorized representatives of patients must read and speak English Exclusion Criteria: * Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors
References
Publications (0)
Data not yet available
No reference posted for this study.